Iambic Therapeutics to Present New Pre-Clinical Data for IAM1363, a Selective and Brain-Penetrant Inhibitor of Both HER2 Wild-Type and Oncogenic Mutants, at the 2024 AACR Annual Meeting
March 28 2024 - 10:00AM
Business Wire
Iambic Therapeutics today announced it will highlight new
preclinical data for IAM1363, a selective and brain-penetrant
inhibitor of HER2 signaling for the treatment of HER2-driven
cancers, in a poster presentation at the American Association for
Cancer Research (AACR) Annual Meeting, taking place April 5-10 in
San Diego.
The poster presentation will showcase preclinical data
illustrating how the unique binding mechanism and potent HER2
activity of IAM1363 overcomes multiple resistance mechanisms and
how its strong EGFR avoidance widens the safety margin. IAM1363
potently inhibits both the wild type and mutant forms of HER2,
showing over 1000-fold selectivity against EGFR due to a unique
binding mode and tumor enhancement not seen with other HER2
inhibitors, leading to exceptional in vivo efficacy and
tolerability in various HER2-driven cancer models, including those
resistant to existing HER2-targeting agents. IAM1363 is now in a
Phase 1 clinical study.
Poster Presentation Details:
Presentation Title: Validation of a novel Type II HER2
inhibitor through preclinical studies across various cancer
models
Abstract Number: 1980/29
Session Title: Kinase and Phosphatase Inhibitors 2
Location: Poster Section 25
Date and Time: Monday, April 8th; 9:00 – 12:30 PT
Presenter: Lana Kulyk, PhD
About Iambic Therapeutics
Founded in 2019 and headquartered in San Diego, California,
Iambic Therapeutics is disrupting the therapeutics landscape with
its unique AI-driven drug-discovery platform. Iambic has assembled
a world-class team that unites pioneering AI experts and
experienced drug hunters with strong track records of success in
delivering clinically validated therapeutics. The Iambic platform
has been demonstrated to deliver high-quality, differentiated
therapeutics to clinical stage with unprecedented speed and across
multiple target classes and mechanisms of action. The Iambic team
is advancing an internal pipeline of clinical assets to address
urgent unmet patient needs. Learn more about the Iambic team,
platform, and pipeline at iambic.ai.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240328062386/en/
Jason Glashow Glashow Strategic Communications for Iambic
Jason.Glashow@iambic.ai